EBI-005
Phase 3Small molecule
EBI-005 is one of 56 small molecule programs targeting Allergic Conjunctivitis. It is currently in Phase 3.
2
Indications
2
Total Trials
0
Active Trials
55
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
200 competitors in Eye Disease
#DrugCompanyPhaseTrials
1Zovirax
BBp Consulting, Inc
Phase 3
Aquasol E
NNational Eye Institute (NEI)
Phase 3
CF101
CCan-Fite BioPharma
Phase 3
Carboxymethylcellulose
AbbViePhase 3
Refresh Plus
AbbViePhase 3
Csa
ZZhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
Phase 3
Diquafosol Tetrasodium
Merck & Co.Phase 3
ABBV-444
AbbViePhase 3
EBI-005
EEleven Biotherapeutics
Phase 3
Active Comparator EBI-005
EEleven Biotherapeutics
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for EBI-005. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- EEleven Biotherapeutics